Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf145 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Tarek El Hindi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines Business Unit, Takeda Pharmaceuticals International AG, Zurich, Switzerland. Hauptthemen laut MEDLINE: Dengue, Dengue Vaccines, Asymptomatic Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Vaccines, Inc..
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
TAK-003 has been shown to be well tolerated and effective against symptomatic dengue disease and hospitalization, irrespective of baseline serostatus. Most infections are asymptomatic/subclinical. This study assessed whether TAK-003 could protect against asymptomatic/subclinical infections by evaluating increased neutralizing antibody (NAb) titers after natural infection.
Methods
DEN-301 (NCT02747927) is a phase 3 trial among 4- to 16-year-old participants who received 2 doses of TAK-003 or placebo 3 months apart. These exploratory analyses used NAb measured during the trial. As no well-accepted definition for asymptomatic infection exists, 3 algorithms were evaluated: (1) 4-fold increase in NAb, (2) 4-fold increase in NAb and a minimum titer of 40, and (3) 4-fold increase in NAb and a minimum titer of 4-fold lower limit of quantification. Months 4 to 9, months 9 to 15, and months 15 to 27 after first vaccination were analyzed.
Results
NAbs from 3765 participants were analyzed. From months 4 to 9, vaccine efficacy (VE) against asymptomatic infection was 51.1% (95% CI, 30.4%–65.6%), 36.1% (95% CI, 6.7%–56.3%), and 27.3% (95% CI, −8.2% to 51.2%) for algorithms 1, 2, and 3, respectively. VE per algorithms 1, 2, and 3 was 54.8% (95% CI, 28.8%–71.3%), 47.9% (95% CI, 16.8%–67.4%), and 44.3% (95% CI, 9.9%–65.6%) in participants with baseline seropositivity and 44.4% (95% CI, 2.1%–68.4%), 4.6% (95% CI, −85.1% to 50.8%), and −29.3% (95% CI, −172.1% to 38.6%) in those with baseline seronegativity. VE against asymptomatic infection gradually decreased from months 4 to 9 to months 9 to 15 and from months 9 to 15 to months 15 to 27.
Conclusions
The variability in VE algorithms indicates challenges in accurately assessing VE against asymptomatic infections. TAK-003 had a modest impact on asymptomatic dengue infections in the first months postvaccination, mainly in participants with baseline seropositivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vaccines Business Unit, Takeda Pharmaceuticals International AG, Zurich, Switzerland.
- Virology Research Unit, Philippines-Armed Forces Research Institute of Medical Sciences, Cebu City.
- University of the Philippines Manila.
- Centro de Pesquisa Clínica, Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Salvador, Brazil.
- Escola Superior de Ciências da Santa Casa de Misericórdia de Vitória, Brazil.
- University of Alabama, Birmingham.
ORCID-Profile: Lulu Bravo, Ana Lucia Oliveira, Vianney Tricou, Nicolas Folschweiller
Förderung
- Takeda Vaccines, Inc.
Zitieren
APA
El Hindi, T., Alera, M. T., Bravo, L., Moreira, E. D., Dietze, R., Oliveira, A. L., Watanaveeradej, V., Zhao, Y., Sonderegger, I., Tricou, V., Folschweiller, N., & Biswal, S. (2025). Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf145
Vancouver
El Hindi T, Alera MT, Bravo L, Moreira ED, Dietze R, Oliveira AL, et al. Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf145
BibTeX
@article{ElHindi2025,
author = {El Hindi, Tarek and Alera, Maria Theresa and Bravo, Lulu and Moreira, Edson Duarte and Dietze, Reynaldo and Oliveira, Ana Lucia and Watanaveeradej, Veerachai and Zhao, Yuan and Sonderegger, Ivo and Tricou, Vianney and Folschweiller, Nicolas and Biswal, Shibadas},
title = {Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf145}
}
EUVIMED